The importance of cross‐disciplinary scientific engagement in the development of quantitative procedures for aggregate safety assessments
Authors:
- 22 May 2019
- journal article
- editorial
- Published by Wiley in Pharmaceutical Statistics
- Vol. 18 (5) , 510-512
Abstract
Recent guidance on safety monitoring during drug development, issued by regulatory authorities in the United States and European Union, indicate a shift in focus towards aggregate safety monitoring and scientific evaluation of integrated safety data. The call for program‐level reviews of accumulating safety data, including from ongoing studies, provides an opportunity to leverage the scientific expertise and medical judgment of safety management teams with (a) a multidisciplinary approach, (b) quantitative frameworks to measure level of evidence, and (c) assessments that are product‐specific and driven by medical judgment. A multidisciplinary team, regularly reviewing aggregate safety data throughout the development program, is vital not only for early signal detection but also for generating a better understanding of the accumulating data and context needed for decreasing false alarms.Keywords
This publication has 11 references indexed in Scilit:
- Bayesian detection of potential risk using inference on blinded safety dataPharmaceutical Statistics, 2018
- Blinded Safety Signal Monitoring for the FDA IND Reporting Final Rule2016
- A Bayesian Exposure-Time Method for Clinical Trial Safety Monitoring With Blinded DataTherapeutic Innovation & Regulatory Science, 2016
- Monitoring potential adverse event rate differences using data from blinded trials: the canary in the coal mineStatistics in Medicine, 2016
- Control charts for monitoring accumulating adverse event count frequencies from single and multiple blinded trialsStatistics in Medicine, 2016
- Reporting Adverse Drug Reactions in Product LabelsTherapeutic Innovation & Regulatory Science, 2016
- The FDA's Final Rule on Expedited Safety Reporting: Statistical ConsiderationsStatistics in Biopharmaceutical Research, 2015
- Willful Ignorance2014
- Continuous safety monitoring for randomized controlled clinical trials with blinded treatment informationContemporary Clinical Trials, 2011
- Reporting cumulative proportion of subjects with an adverse event based on data from multiple studiesPharmaceutical Statistics, 2011